Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Active, not recruiting · Phase 3 · NCT05169567
Conditions: Breast Neoplasm, Neoplasm Metastasis
At a glance
- Research payments reported, 2025
- $480,599
- U.S. investigators named
- 22
- Sites paid
- 18
- Planned or actual enrollment
- 368
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Abemaciclib (drug), Fulvestrant (drug), Placebo (drug)
- Dates
- Started 2022-03-11; completion 2027-12
- Results posted
- Yes
This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
From ClinicalTrials.gov, last updated 2026-10-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $480,599 in research payments for this study in 2025 (33 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- J T. Beck, M.D., F.A.C.P. Hematology & Oncology · Springdale, AR
- Rena D. Callahan, M.D. Internal Medicine · Valencia, CA
- David D. Chang, MD Hematology & Oncology · Los Angeles, CA
- Giribala R. Patel, M.D. Medical Oncology · Fullerton, CA
- Mabel A. Mardones, M.D. Hematology & Oncology · Denver, CO
- Shaachi Gupta, MD Medical Oncology · West Palm Beach, FL
- Elisa Krill-jackson, MD Hematology & Oncology · Miami, FL
- Rami S. Owera, M.D. Medical Oncology · Pensacola, FL
- Meredith Faggen, M.D. Hematology & Oncology · S Weymouth, MA
- Rinath M. Jeselsohn, M.D. Medical Oncology · Boston, MA
- Seth A. Wander, MD,PHD Hematology & Oncology · Boston, MA
- Carol K. Tweed, MD Medical Oncology · Annapolis, MD
- Stephanie L. Graff, M.D. Hematology & Oncology · Kansas City, MO
- Jeanna H. Walsh, MD Hematology & Oncology · Concord, NH
- Bernard Tawfik, MD Hematology & Oncology · Albuquerque, NM
- Kevin M. Kalinsky, M.D. Medical Oncology · New York, NY
- Brooke E. Daniel, MD Hematology & Oncology · Chattanooga, TN
- Virginia Kaklamani, MD Medical Oncology · San Antonio, TX
- Charles V. Kurkul, M.D. Hematology & Oncology · Denton, TX
- Ines J. Sanchez-rivera, M.D. Medical Oncology · El Paso, TX
- Zachary L. Reese, M.D. Hematology & Oncology · St George, UT
- Anne M. Favret, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Intermountain Health Utah Valley Hospital, UT $165,442
- University of Miami $41,469
- Emory University Hospital, GA $37,157
- Univ of Tx Health Sciences Center at San Antonio $25,753
- US Oncology Research LLC $25,228
- New Mexico Cancer Care Alliance $25,143
- Rocky Mountain Cancer Centers LLP $23,096
- Ronald Reagan UCLA Medical Center, CA $22,714
- Maryland Oncology Hematology PA $16,865
- Dana Farber PArtners Cancer Care Inc $16,833
- Highlands Oncology Group PA $16,143
- Texas Oncology PA $15,221
- Fairfax-Northern Virginia $13,300
- Rhode Island Hospital, RI $12,115
- Sarah Cannon Research Institute LLC $9,379
- Translational Oncology Research International Inc $8,576
- Woodlands Medical Specialists $4,166
- Florida Cancer Specialists $1,998
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.